Barcelona, September 20th, 2019
The Company
STALICLA is a near clinical Company developing a first in class precision medicine platform
to accelerate drug development for patients Neurodevelopmental Disorders (NDD). First
focus of development has been Autism Spectrum Disorder (ASD). Today, patients diagnosed
with ASD account for 1-1.5% of the world population. The condition remains a high unmet
medical need.
In its Geneva and Barcelona units, STALICLA has assembled a world class team of
experienced drug developers and computational biologists. The company is recognized as a
disruptive player, using its DEPIv3 AI & statistical modelling platform to identify subgroups
of patients with ASD and corresponding candidate drugs.
It is the first time that such technologies have been utilized within the field
of neurodevelopment with the potential to change the direction of the specialty.
Patients are then characterized through biomarker preclinical and clinical investigations.
In just over 2 years, the STALICLA platform has already proven successful in
expediting and de-risking drug development for a first subgroup of patients with
Autism and identifying two additional subgroups.
STALICLA’s first therapeutic package - STP1 - addresses a distinct sub-group of ASD patients
estimated to 1.5-2M people in the EU and North America. Clinical entry for STP1 is planned
in Q1 2020.
To support its platform and pipeline development, STALICLA has developed a network of top
tier research and clinical partners in the US.
This has enabled STALICLA to gather one of the largest Autism patient Electronic Health
Record databases to date.
STALICLA is currently applying its DEPIv3 discovery model to advance new pipelines for
additional groups of patients.
In Q1 2019 – Three new modules have been added to the DEPIv3 platform, exponentially
increasing its capacities for single and combination drug repositioning and for identification
of clinical trial stage drug high responder patients.
Background
STALICLA is expanding on its R&D computational systems biology unit in Barcelona. The
research and development unit of STALICLA in Spain focuses on the identification of
subgroups of patients based on genetic, phenotypic and clinical factors, integrating
molecular, anatomical and medical data. Through biomedical big data analysis, the research
unit leverages on existing molecular entities to bring tailored treatments to patients with
NDDs. The fundamental elements of DEPIv3 include the computational analysis of omics
data (proteomics, genomics, transcriptomics, metabolomics, etc.) and personalized systems
medicine. Analysis involves statistical modeling and machine learning centered on the
biology of diseases, comorbidities and pharmacology.
World Trade Center | Moll de Barcelona, s/n, Edif Este | 08039 Barcelona | Spain | + 34 931 682 868
Position
Position Title: Computational Biologist Intern
Location: World Trade Center, Barcelona
Duration: 3 to 6 months
The role
The intern will participate in biomedical data analysis within the context of ongoing
computational systems biology projects, ranging from the identification of biological
processes and pathways enriched for genes associated with conditions comorbid across
neurodevelopmental disorders (NDDs), extraction and curation of features for the
characterization of NDD subgroups, maintenance/deployment of our next-generation
sequencing pipelines, and clinical data mining. The intern will work closely with other
members of the unit to integrate genomics and phenotype data to better understand how
genes work together at the systems biology level to alter risk for autism and other
neuropsychiatric disorders.
Work environment and supervision
The STALICLA R&D office is located by the sea, overlooking the port of Barcelona, and it has
easy access to the public transportation. Gigs at the office include free coffee, tea and fresh
fruits. The intern will have complete supervision until the desired technical skill level is
reached and the independence on satisfactorily performing assigned tasks is demonstrated.
After competence is reached, minimal supervision should be necessary unless requested.
Candidates with previous experience on next-generation sequencing analysis and/or
biomedical text mining, or who are open to learning these skills, are preferred.
Desired skills & software
Application procedure
Please send a copy of your CV along with the info on your availability (starting date and
internship duration) to info@stalicla.com
World Trade Center | Moll de Barcelona, s/n, Edif Este | 08039 Barcelona | Spain | + 34 931 682 868